Please have a look at our editorial published in #ASCODailyNews @ascocancer.bsky.social @antoniodalessio.bsky.social @cirocelsa.bsky.social From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma dailynews.ascopubs.org/do/sorafenib...

📣Now online our new study on #GLP1RA and liver outcomes!🔬 GLP-1 agonists reduce risk of major liver events in T2 diabetes pts. Meta-analysis of 1.4+ million pts shows ⬇️ risk of decompensation and potential reduction in HCC @giuseppecabibbo.bsky.social @djpinato.bsky.social doi.org/10.1136/gutj...

In press on @amergastroassn.bsky.social journal CGH our multicenter study on 293 pts with PBC from Italy/UK 🔥 Non-invasive tests for portal hypertension perform poorly when cholestasis is severe. 👊RESIST criteria (PLT+albumin) outperform stiffness-based criteria www.cghjournal.org/article/S154...

Thrilled to have participated in EASL-AASLD Masterclass in beautiful #Savannah. Amazing opportunity to exchange insights, networking and advance expertise in #liver diseases with global leaders. Grateful for this enriching experience! #Liversky

OUR TEAM WON Proud mama over here